SuperworthCandel Therapeutics CADL
- Market cap
- $614.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −9.3%
Candel Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $5.8M+9% | $7.3M+46% | $4.1M−25% | $5M−16% | $5.4M−7% | $4.8M−34% | $4M−2% | $7M+40% | $8.5M+56% | $11M+129% | $9.8M+145% | $19.8M+183% |
| SG&A | $3M−15% | $3.1M−3% | $3.8M−9% | $3.6M−2% | $3.3M+11% | $3.3M+9% | $4.1M+8% | $4.2M+17% | $4.7M+42% | $4.7M+42% | $6.4M+57% | $6.9M+66% |
| −$8.9M−0% | −$10.3M+27% | −$7.9M−18% | −$8.6M−11% | −$8.8M−1% | −$8.1M−21% | −$8.1M+3% | −$11.2M+30% | −$13.2M+51% | −$15.8M+94% | −$16.3M+100% | −$26.7M+139% | |
| Interest expense | $669K+29% | $673K+16% | $646K+6% | $567K−12% | $487K−27% | $390K−42% | $306K−53% | $236K−58% | $161K−67% | $1.4M+263% | $1.6M+411% | $1.6M+567% |
| Net income | −$8.4M−3% | −$11.1M+118% | −$8.2M−7% | −$22.2M+131% | −$10.6M+26% | −$14.1M+27% | $7.4M | −$4.8M−78% | −$11.3M+6% | −$29.5M+110% | −$8.9M | −$38.9M+711% |
| −$0.29−3% | −$0.38+111% | −$0.28−7% | −$0.74+124% | −$0.33+14% | −$0.40+5% | $0.13 | −$0.09−88% | −$0.21−36% | −$0.54+35% | −$0.14 | −$0.52+478% | |
| 28.9M+0% | 29M+0% | 29.2M+1% | 29.9M+3% | 32M+11% | 35.6M+23% | 54.8M+88% | 51.5M+72% | 54.9M+72% | 54.9M+54% | 62.4M+14% | 74.1M+44% |
Revenue: Q1 FY20: 6 months less the 3 months printed beside them.
R&D: Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 5 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Candel Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CADLCandel Therapeutics | $614.4M | n/m | n/a | n/m | n/m | n/m | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| Peer median | $1.5B | 14.1× | 27.8× | 3.6× | +23% | 21.7% |
More on Candel Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .